bioRxiv/medRxiv TRiP Review Activity

412 Reviews — All Partners — Cancer Biology

Most recent first Previous |  Page 8: Articles 71-80  | Next

Deuterium Metabolic Imaging Phenotypes Mouse Glioblastoma Heterogeneity Through Glucose Turnover Kinetics
Simoes, R. V., Henriques, R. N., Olesen, J. L., Cardoso, B. M., Fernandes, F. F., Monteiro, M. A., Jespersen, S., Carvalho, T., Shemesh, N.
10.1101/2024.06.23.600246 — Posted: 2024-06-29 — Discussion: 2025-01-30  eLife
NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in Solitary Fibrous Tumors
Hill, C., Indeglia, A., Picone, F., Murphy, M., Cipriano, C., Maki, R. G., Gardini, A.
10.1101/2024.04.15.589533 — Posted: 2024-04-20 — Discussion: 2025-01-30  eLife
Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
Kim, T., Park, B.-S., Heo, S., Jeon, H., Kim, J., Kim, D., Kook Lee, S., Jung, S.-Y., Kong, S.-Y., Lu, T.
10.1101/2023.11.08.566220 — Posted: 2023-11-08 — Discussion: 2025-01-29  eLife
Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs and CD8+ T cells
Dong, F., Zhang, S., Song, K., Jiang, L., Hu, L.-P., Li, Q., Zhang, X.-L., li, j., Feng, M., Cai, Z.-W., Yao, H.-F., Li, R.-k., Li, H., Chen, J., Hu, X., Wang, J., Jiang, C., Zhu, H. H., Wang, C., Da, L., Zhang, Z., Bao, Z., Wang, X., Jiang, S.
10.1101/2024.10.15.618536 — Posted: 2024-10-18 — Discussion: 2025-01-28  eLife
Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis.
Korelova, K., Prechova, M., Frick, L., Sarnova, L., Bisht, P., Novotna, P., Kosla, J., Bortel, P., Borutzki, Y., Bileck, A., Gerner, C., Rahbari, M., Rahbari, N., Birgin, E., Kvasnicova, B., Galisova, A., Sulkova, K., Bauer, A., Jobe, N., Tolde, O., Sticova, E., Rosel, D., O Connor, T., Otahal, M., Jirak, D., Heikenwalder, M., Wiche, G., Meier-Menches, S. M., Gregor, M.
10.1101/2024.08.02.606331 — Posted: 2024-08-06 — Discussion: 2025-01-27  eLife
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
Armand, J., Kim, S., Kim, K., Son, E., Kim, M., Yang, H. W.
10.1101/2024.11.11.623139 — Posted: 2024-11-15 — Discussion: 2025-01-24  eLife
Non-destructive in situ monitoring of structural changes of 3D tumor spheroids during the formation, migration, and fusion process
Ning, K., Xie, Y., Sun, W., Feng, L., Fang, C., Pan, R., Li, Y., Yu, L.
10.1101/2024.07.25.605064 — Posted: 2024-07-25 — Discussion: 2025-01-23  eLife
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning
Estevam, G. O., Linossi, E. M., Rao, J., Macdonald, C. B., Ravikumar, A., Chrispens, K. M., Capra, J. A., Coyote-Maestas, W., Pimentel, H., Collisson, E. A., Jura, N., Fraser, J. S.
10.1101/2024.07.16.603579 — Posted: 2024-07-18 — Discussion: 2025-01-23  eLife
Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer
Zhang, Y., Wang, H., Wei, Y., Pan, Y., Song, X., Shi, T., Shao, J., Yu, L., Liu, B., Wang, Y., Wei, J.
10.1101/2024.11.04.621870 — Posted: 2024-11-06 — Discussion: 2025-01-16  eLife
Replication stress inducing ELF3 upregulation promotes BRCA1-deficient breast tumorigenesis in luminal progenitors
Zhou, J., Zhou, X. A., Hu, L., Ma, Y., Zhan, J., Xu, Z., Zhou, M., Shen, Q., Xie, Y., Wang, J.
10.1101/2023.07.20.549893 — Posted: 2023-07-20 — Discussion: 2025-01-02  eLife

Evaluation Sources